FDA Oncology Announcements

RET inhibitor × Clear all

9 Announcements

FDA approves selpercatinib for medullary thyroid cancer with a RET mutation

Trial: LIBRETTO-531
Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Endocrine

FDA approves selpercatinib for RET fusion-positive thyroid cancer

Trials: LIBRETTO-001, LIBRETTO-121
Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Endocrine

FDA grants accelerated approval to selpercatinib for pediatric patients two years and older with RET-altered metastatic thyroid cancer or solid tumors

Drug: Retevmo (selpercatinib) · RET inhibitor
Conditions: EndocrineOther solid neoplasm

FDA approves pralsetinib for non-small cell lung cancer with RET gene fusions

Trial: ARROW
Drug: Gavreto (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive non-small cell lung cancer

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors

Drug: Retevmo (selpercatinib) · RET inhibitor
Condition: Other solid neoplasm

FDA approves pralsetinib for RET-altered thyroid cancers

Trial: ARROW
Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Endocrine

FDA approves pralsetinib for lung cancer with RET gene fusions

Drug: GAVRETO (pralsetinib) · RET inhibitor
Condition: Thoracic

FDA approves selpercatinib for lung and thyroid cancers with RET gene mutations or fusions

Drug: RETEVMO (selpercatinib) · RET inhibitor
Condition: Endocrine